Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing

Jacob Appelbaum(National Cancer Institute), Michael C. Jensen(Seattle Children's Hospital), Michael Fitzgerald(Seattle Children's Hospital), William Crago(Ambrx (United States)), Joshua A. Gustafson(Seattle Children's Hospital), Semanti Sarkar(Seattle Children's Hospital), Secil Franke-Welch(Biogen (United States)), Jordan Jarjour(Biogen (United States)), Kaori Oda(Seattle Children's Hospital), Adam J. Lamble(Seattle Children's Hospital), Stephanie Rawlings-Rhea(Seattle Children's Hospital), Daniel E. Zak(Center for Infectious Disease Research), Mark Pogson(ETH Zurich), Andrew Hollands(Torrey Pines Institute For Molecular Studies), Unja Martin(Biogen (United States)), Brendan P. Eckelman(Ambrx (United States)), Njabulo Ngwenyama(Norwegian Womens Public Health Association), Sarah K. Hilton(Biogen (United States)), Anne-Rachel Krostag(Allen Institute for Brain Science), Alexander Astrakhan(Seattle University), Rebecca Gardner(Seattle Children's Hospital), Niklas Tulberg(Seattle Children's Hospital), Giacomo Tampella(Seattle Children's Hospital), Sanela Bilic, Paula Lewis, April E. Price(Biogen (United States)), John C. Timmer(Torrey Pines Institute For Molecular Studies), Claudya Evandy(Seattle Children's Hospital), Angelica Sanabria(Torrey Pines Institute For Molecular Studies), Dong Xia(Biogen (United States)), Philip D. Gregory(Biogen (United States)), Marissa Leonardi(Seattle Children's Hospital), Wai‐Hang Leung(Biogen (United States)), Joy Zhang(McGill University), Jim Woodworth(Waukesha County Technical College), Pauline Pl So(Biogen (United States)), Rachael Logan(Seattle Children's Hospital), Kyle M. L. Jones(Torrey Pines Institute For Molecular Studies)
Journal of Clinical Investigation
March 19, 2024
Cited by 51


Related Papers